{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T21:29:39Z","timestamp":1775338179618,"version":"3.50.1"},"reference-count":45,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Cardiovascular disease (CVD) remains a major problem for people with type 2 diabetes (T2DM), and the leading cause of death worldwide. We aimed to determine cardiovascular benefits of weight loss with or without remission of diabetes, and to assess utility of plasma biomarkers. 29 people with T2DM were studied at baseline and after dietary weight loss. Change in plasma adipokines and lipid related markers was examined in relation to weight loss, diabetes remission, 10-year cardiovascular risk (QRISK), and duration of diabetes. QRISK decreased markedly after weight loss (18.9 \u00b1 2.2 to 11.2 \u00b1 1.6%, p &lt; 0.0001) in both responders and non-responders, but non-responders remained at higher risk (15.0 \u00b1 2.0 vs. 5.8 \u00b1 1.6%, p &lt; 0.0001). At baseline, plasma GDF-15 was higher in longer diabetes duration (1.19 \u00b1 0.14 vs. 0.82 \u00b1 0.09 ng\/mL, p = 0.034), as was the QRISK (22.8 \u00b1 2.6 vs. 15.3 \u00b1 3.4%, p = 0.031). Leptin, GDF-15 and FGF-21 decreased whereases adiponectin increased after weight loss in responders and non-responders. However, the level of FGF-21 remained higher in non-responders (0.58 [0.28\u20130.71] vs. 0.25 [0.15\u20130.42] ng\/mL, p = 0.007). QRISK change correlated with change in plasma VLDL1-TG (r = 0.489, p = 0.007). There was a positive correlation between rise in HDL cholesterol and the decrease in leptin (r = 0.57, p = 0.001), or rise in adiponectin (r = 0.58, p = 0.001) levels. In conclusion, weight loss markedly decreases cardiometabolic risk particularly when remission of diabetes is achieved. Leptin, adiponectin, GDF-15 and FGF-21 changes were related to weight loss not remission of diabetes. Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.<\/jats:p>","DOI":"10.3390\/nu13051465","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T06:19:11Z","timestamp":1619504351000},"page":"1465","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effect of Weight Loss by Low-Calorie Diet on Cardiovascular Health in Type 2 Diabetes: An Interventional Cohort Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3079-8055","authenticated-orcid":false,"given":"Shaden","family":"Melhem","sequence":"first","affiliation":[{"name":"Translational and Clinical Research Institute, Magnetic Resonance Centre, Newcastle University, Newcastle upon Tyne NE4 5PL, UK"},{"name":"Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH16 4TJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Steven","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Magnetic Resonance Centre, Newcastle University, Newcastle upon Tyne NE4 5PL, UK"},{"name":"Manchester Diabetes &amp; Endocrinology Centre, Manchester Royal Infirmary, Manchester M13 9WL, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6273-0170","authenticated-orcid":false,"given":"Roy","family":"Taylor","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Magnetic Resonance Centre, Newcastle University, Newcastle upon Tyne NE4 5PL, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3689-1266","authenticated-orcid":false,"given":"Ahmad","family":"Al-Mrabeh","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Magnetic Resonance Centre, Newcastle University, Newcastle upon Tyne NE4 5PL, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","article-title":"Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015","volume":"70","author":"Roth","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Al-Mrabeh, A. (2021). \u03b2-Cell Dysfunction, Hepatic Lipid Metabolism, and Cardiovascular Health in Type 2 Diabetes: New Directions of Research and Novel Therapeutic Strategies. Biomedicines, 9.","DOI":"10.3390\/biomedicines9020226"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2337\/dc15-1942","article-title":"Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders","volume":"39","author":"Steven","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial","volume":"7","author":"Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cmet.2019.11.018","article-title":"Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss","volume":"31","author":"Zhyzhneuskaya","year":"2020","journal-title":"Cell Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S2213-8587(20)30303-X","article-title":"2-year remission of type 2 diabetes and pancreas morphology: A post-hoc analysis of the DiRECT open-label, cluster-randomised trial","volume":"8","author":"Hollingsworth","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of Very Low\u2013Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome","volume":"28","author":"Adiels","year":"2008","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/XCE.0000000000000201","article-title":"Pathogenesis and remission of type 2 diabetes: What has the twin cycle hypothesis taught us?","volume":"9","year":"2020","journal-title":"Cardiovasc. Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1055\/s-0033-1358519","article-title":"Lipoprotein Metabolism, Dyslipidemia, and Nonalcoholic Fatty Liver Disease","volume":"33","author":"Fisher","year":"2013","journal-title":"Semin. Liver Dis."},{"key":"ref_11","unstructured":"Endotext, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Grossman, A., Hershman, J.M., and Hofland, J. (2019). The Role of Lipids and Lipoproteins in Atherosclerosis, MDText.com, Inc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.2337\/diacare.27.10.2488","article-title":"Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients","volume":"27","author":"Satoh","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jacc.2008.05.060","article-title":"Leptin resistance: A possible interface of inflammation and metabolism in obesity-related cardiovascular disease","volume":"52","author":"Martin","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cmet.2018.12.016","article-title":"GDF15 Provides an Endocrine Signal of Nutritional Stress in Mice and Humans","volume":"29","author":"Patel","year":"2019","journal-title":"Cell Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/03009734.2019.1696430","article-title":"Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: A proteomics approach","volume":"125","author":"Carlsson","year":"2020","journal-title":"Upsala J. Med. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1007\/s00125-019-4913-2","article-title":"The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: A Mendelian randomisation study","volume":"62","author":"Yeung","year":"2019","journal-title":"Diabetologia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2337\/dc08-1458","article-title":"Leptin Predicts Diabetes but Not Cardiovascular Disease: Results from a large prospective study in an elderly population","volume":"32","author":"Welsh","year":"2008","journal-title":"Diabetes Care"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-015-0208-1","article-title":"Serum leptin levels are independently related to the incidence of ischemic heart disease in a prospective study of patients with type 2 diabetes","volume":"14","author":"Vavruch","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-016-0492-4","article-title":"Leptin and adiponectin as predictors of cardiovascular risk after gestational diabetes mellitus","volume":"16","author":"Lekva","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.106.171016","article-title":"Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism","volume":"113","author":"Poirier","year":"2006","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1007\/s00125-011-2204-7","article-title":"Reversal of type 2 diabetes: Normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol","volume":"54","author":"Lim","year":"2011","journal-title":"Diabetologia"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Al-Mrabeh, A., Hollingsworth, K.G., Steven, S., Tiniakos, D., and Taylor, R. (2017). Quantification of intrapancreatic fat in type 2 diabetes by MRI. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174660"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00125-016-3984-6","article-title":"Morphology of the pancreas in type 2 diabetes: Effect of weight loss with or without normalisation of insulin secretory capacity","volume":"59","author":"Hollingsworth","year":"2016","journal-title":"Diabetologia"},{"key":"ref_25","first-page":"j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: Prospective cohort study","volume":"357","author":"Coupland","year":"2017","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100355","DOI":"10.1016\/j.xpro.2021.100355","article-title":"Measurement of intraorgan fat and hepatic output of triglycerides in human type 2 diabetes by magnetic resonance and intralipid infusion techniques","volume":"2","author":"Peters","year":"2021","journal-title":"STAR Protoc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cmet.2018.07.003","article-title":"Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for beta cell recovery","volume":"28","author":"Taylor","year":"2018","journal-title":"Cell Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1161\/CIRCULATIONAHA.118.037885","article-title":"Age at Diagnosis of Type 2 Diabetes Mellitus and Associations with Cardiovascular and Mortality Risks","volume":"139","author":"Sattar","year":"2019","journal-title":"Circulation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00125-020-05322-1","article-title":"Increased particle size of triacylglycerol-enriched remnant lipoproteins, but not their plasma concentration or lipid content, augments risk prediction of incident type 2 diabetes","volume":"64","author":"Carvalho","year":"2021","journal-title":"Diabetologia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-020-01292-w","article-title":"Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol","volume":"19","author":"Fonseca","year":"2020","journal-title":"Lipids Health Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2016.11.065","article-title":"Very-Low-Density Lipoprotein\u2013Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III","volume":"69","author":"Pechlaner","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1194\/jlr.M093740","article-title":"ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance","volume":"60","author":"Ramms","year":"2019","journal-title":"J. Lipid Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sofat, R., Cooper, J.A., Kumari, M., Casas, J.P., Mitchell, J.P., Acharya, J., Thom, S., Hughes, A.D., Humphries, S.E., and Hingorani, A.D. (2016). Circulating Apolipoprotein E Concentration and Cardiovascular Disease Risk: Meta-analysis of Results from Three Studies. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002146"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.clnu.2016.04.027","article-title":"FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss","volume":"36","author":"Domingo","year":"2017","journal-title":"Clin. Nutr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/oby.21658","article-title":"Fibroblast growth factor 21 correlates with weight loss after vertical sleeve gastrectomy in adolescents","volume":"24","author":"Khan","year":"2016","journal-title":"Obesity"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1101\/gad.177857.111","article-title":"FGF21 regulates PGC-1\u03b1 and browning of white adipose tissues in adaptive thermogenesis","volume":"26","author":"Fisher","year":"2012","journal-title":"Genes Dev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41467-017-02677-9","article-title":"Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2337\/dbi19-0018","article-title":"Leptin: Less Is More","volume":"69","author":"Zhao","year":"2020","journal-title":"Diabetes"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/joim.12062","article-title":"Effects of individual and combined dietary weight loss and exercise interventions in postmenopausal women on adiponectin and leptin levels","volume":"274","author":"Abbenhardt","year":"2013","journal-title":"J. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1210\/jc.2016-1207","article-title":"Weight-Loss Diets, Adiponectin, and Changes in Cardiometabolic Risk in the 2-Year POUNDS Lost Trial","volume":"101","author":"Ma","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Unamuno, X., Izaguirre, M., G\u00f3mez-Ambrosi, J., Rodr\u00edguez, A., Ram\u00edrez, B., Becerril, S., Valent\u00ed, V., Moncada, R., Silva, C., and Salvador, J. (2019). Increase of the Adiponectin\/Leptin Ratio in Patients with Obesity and Type 2 Diabetes after Roux-en-Y Gastric Bypass. Nutrients, 11.","DOI":"10.3390\/nu11092069"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hakim, O., Bello, O., Ladwa, M., Peacock, J.L., Umpleby, A.M., Charles-Edwards, G., Amiel, S.A., and Goff, L.M. (2020). The Link between Obesity and Inflammatory Markers in the Development of Type 2 Diabetes in Men of Black African and White European Ethnicity. Nutrients, 12.","DOI":"10.3390\/nu12123796"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) Reduction in Persons with Cardiovascular Disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/13\/5\/1465\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:52:47Z","timestamp":1760161967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/13\/5\/1465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["nu13051465"],"URL":"https:\/\/doi.org\/10.3390\/nu13051465","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]}}}